IC
URGN icon

IEQ Capital’s UroGen Pharma URGN Stock Holding History

IEQ Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,250
Closed -$236K – 383
2020
Q3 		$236K Hold
12,250
– – 0.01% 338
2020
Q2 		$320K Hold
12,250
– – 0.02% 235
2020
Q1 		$219K Hold
12,250
– – 0.02% 323
2019
Q4 		$409K Buy
+12,250
New +$334K 0.04% 254

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

IEQ Capital's URGN Position: Q4 2020 in Review

IEQ Capital sold out of UroGen Pharma (URGN) in Q4 2020, closing a stake of 12,250 shares — an estimated $236K sold.

IEQ Capital first reported a position in URGN in Q4 2019 and held it in 4 quarters. The position peaked at $409K in Q4 2019. 81 funds tracked by Wall St. Rank hold URGN as of Q4 2020.

  • IEQ Capital reported no remaining UroGen Pharma position as of Q4 2020 after selling out during the quarter.
  • IEQ Capital sold 12,250 UroGen Pharma shares in Q4 2020, an estimated $236K.
  • IEQ Capital first reported a position in UroGen Pharma in Q4 2019 and held it in 4 quarters.
  • IEQ Capital's UroGen Pharma position peaked at $409K in Q4 2019.
  • 81 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2020.

Based on IEQ Capital's 13F filing for Q4 2020, filed 3 Feb 2021.